Non-small Cell Lung Cancer (NSCLC) Clinical Trials in Fairfax, Virginia

15 studies are recruiting for non-small cell lung cancer (nsclc) in Fairfax, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

   This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology Virginia, Fairfax, Virginia

   Locations

   20 in total

   Run by

   IDEAYA Biosciences

   See if you can join NCT07277413 on ClinicalTrials.gov

2. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT - Virginia, Fairfax, Virginia

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07349537 on ClinicalTrials.gov

3. Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

   TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Fairfax, Virginia

   Locations

   206 in total

   Run by

   AstraZeneca

   See if you can join NCT07291037 on ClinicalTrials.gov

4. A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

   This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   9 in total

   Run by

   Sutro Biopharma, Inc.

   See if you can join NCT07227168 on ClinicalTrials.gov

5. Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

   This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active dru…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Virginia Cancer Specialists, Fairfax, Virginia

   Locations

   74 in total

   Run by

   Genmab

   See if you can join NCT07288177 on ClinicalTrials.gov

6. A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

   Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some people with non small cell lung cancer (NSCLC) have a faulty ALK gene. ALK stands for anaplastic ly…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Virginia Cancer Specialists PC, Fairfax, Virginia

   Locations

   17 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT07140016 on ClinicalTrials.gov

7. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

   This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology Virginia, Fairfax, Virginia

   Locations

   55 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06128551 on ClinicalTrials.gov

8. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07397338 on ClinicalTrials.gov

9. Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

   The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subpro…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology Virginia, Fairfax, Virginia

   Locations

   93 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06162221 on ClinicalTrials.gov

10. A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

    IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants wi…

    Stage

    Phase 1

    Ages

    18 to 99

    Site

    NEXT Virginia, Fairfax, Virginia

    Locations

    11 in total

    Run by

    IDEAYA Biosciences

    See if you can join NCT07540572 on ClinicalTrials.gov

11. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology Virginia, Fairfax, Virginia

    Locations

    17 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT06040541 on ClinicalTrials.gov

12. A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

    The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Virginia, Fairfax, Virginia

    Locations

    8 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07223047 on ClinicalTrials.gov

13. Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

    The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in patients with ROS1-fusion positive stage IB, II, IIIA NSCLC…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Virginia Cancer Specialists, Fairfax, Virginia

    Locations

    33 in total

    Run by

    Nuvation Bio Inc.

    See if you can join NCT07154706 on ClinicalTrials.gov

14. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Next Oncology Virginia, Fairfax, Virginia

    Locations

    21 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT05379985 on ClinicalTrials.gov

15. Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC

    This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacod…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, Fairfax, Virginia

    Run by

    LG Chem

    See if you can join NCT06332755 on ClinicalTrials.gov